Dr. Jonathan Kimmelman is an assistant professor in the Department of Social Studies of Medicine and Biomedical Ethics Unit at McGill University. He holds a PhD in Molecular Biophysics and Biochemistry from Yale University. His research interests revolve around the ethical, social and policy dimensions of biotechnologies.
Dr. Kimmelman's current projects range over concerns such as conflict of interest, description of benefits to trial participants, the ethical justification for initiating first-in-human clinical trials, and the testing of novel interventions against Parkinson's disease. Another area of research involves ethical questions surrounding risk: how should acceptable risk be established, how might ethics committees better evaluate risks, and what risks should be disclosed to prospective trial subjects?
Dr. Kimmelman is principal investigator and coinvestigator on several CIHR-funded operating grants. These variously cover topics like research risk, intellectual property and translational clinical research, and neuroethics.
You need to be logged in to save this episode to a playlist.